News and Press Releases
Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance
First senior executive appointment made following Company launch to oversee strategic development of clinical programmes 23 April 2024 -- Oslo, Norway -- Calluna Pharma, a clinical stage company pioneering a...
Category: Other, Pharmaceutical
Posted: April 23, 2024
Kite to Present Comparison of Outcomes of Tecartus (brexucabtagene autoleucel) from the Pivotal ZUMA-2 Trial Versus the EBMT Registry of alloSCT Patients in Mantle Cell Lymphoma (MCL) at 50th EBMT 2024
Additional analysis demonstrates cost-effectiveness of axicabtagene ciloleucel versus standard of care as second-line therapy In patients With large B-cell lymphoma In Italy 9 April 2024 -- Stockley Park, UK --...
Category: Biotechnology, Clinical Trials
Posted: April 12, 2024
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumour Biology in a Paired Biopsy Clinical Study
NUC-7738 reprogrammes cancer cell lipid metabolism to make tumours less aggressive and promote cancer cell death NUC-7738 alters ribosome biogenesis and the regulation of genes critical for cancer growth and...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: April 10, 2024
G.ST Antivirals reports start of Phase 2 trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer
Phase 2 clinical trial started, first subject in on 2 April 2024 New CMO Ronald Bruce Turner MD, distinguished expert in the clinical research of rhinoviruses, to oversee trial and...
Category: Biotechnology, Clinical Trials
Posted: April 9, 2024
Nonacus launches test for comprehensive genomic profiling, integrated with bioinformatics and analysis software
2 April 2024 -- Birmingham, UK -- Genetic testing company, Nonacus, has launched GALEAS Tumor, a next generation sequencing (NGS) test that provides comprehensive genomic profiling of tumours, allowing clinicians...
Category: Biotechnology
Posted: April 2, 2024
Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham B32 1AF, United Kingdom
Eisbach and Cancer Focus Fund Announce $4.5m Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumours
Eisbach is enabling the potential of synthetic lethality by developing novel compounds to exploit molecular vulnerabilities uniquely present in many hard-to-treat cancers 21 March 2024 -- Martinsried, Germany and Texas, US...
Category: Biotechnology, Pharmaceutical
Posted: March 21, 2024
Kindeva Drug Delivery Welcomes Jennifer Riter, New Vice President of Analytical Services
18 March 2024 -- Minnesota, US, and Missouri, US -- Kindeva Drug Delivery, a global leader in drug-device combination products, today welcomes Jennifer Riter as vice president of Analytical Services to...
Category: Drug Delivery
Posted: March 18, 2024
Faller Packaging announces long-term appointment of new chief executive officer
Dr Michael Faller and Dr Daniel Keesman will step down for reasons of age in the second half of 2024. Dagmar Schmidt will become the new CEO 13 March 2024...
Category: Manufacturing and Packing
Posted: March 13, 2024
Veramed appoints Karen Curran as Chief Strategy Officer
12 March 2024 -- LONDON, UK -- Specialist Biometrics CRO, Veramed, today announced the appointment of Karen Curran as chief strategy officer at Veramed. Karen joins during a period of...
Category: Other
Posted: March 12, 2024
Clinigen boosts senior team with three strategic hires
12 March 2024 -- London, UK -- Clinigen, the global pharmaceutical services company, today announces three strategic appointments to advance its transformation into a world leading pharma services company: Nihad...
Category: Other
Posted: March 12, 2024
ICR scientists seek new drugs to treat childhood cancer as part of global Cancer Grand Challenges team
6 March 2024 -- London, UK -- A global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle...
Category: Clinical Trials, Pharmaceutical
Posted: March 6, 2024
Sequani invests in industry leading facilities as it eyes future growth
26 February 2024 -- Ledbury, UK -- As part of their strategic plans for growth and to meet the evolving needs of modern product developers, Ledbury-based contract research organisation (CRO)...
Category: Drug Discovery
Posted: February 27, 2024
Informed Genomics Limited comments on launch of national BRCA gene testing programme to identify cancer risk early
7 February 2024 -- Birmingham, UK -- NHS England have launched a genetic testing programme targeting tens of thousands of people with Jewish ancestry who are more likely to carry...
Category: Biotechnology
Posted: February 7, 2024
Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham, B32 1AF
First MYC inhibitor to demonstrate safety and anti-tumour activity in a phase 1 first-in-human clinical trial
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has...
Category: Drug Discovery
Posted: February 7, 2024
AES Clean Technology enhances cleanroom construction capabilities through new senior appointment
1 February 2024 -- Pennsylvania, US -- A leading provider of high-performance cleanroom facilities, AES Clean Technology, has announced the appointment of John Costalas to its senior leadership team as...
Category: Manufacturing and Packing
Posted: February 1, 2024
